IDEX Corporation (IEX)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Strong free cash flow generation of $538.9M demonstrates genuine business quality and capital efficiency
• Diversified business across three segments (HST, FMT, FSDP) reduces single-market dependency risk
• Solid recent quarter with 14.27% net margins showing operational execution capability
• Conservative balance sheet with 0.48 D/E ratio provides financial flexibility
• Low beta of 0.96 suggests defensive characteristics despite industrial classification

Concerns

• Valuation is egregiously expensive: trading at 4.3x Graham Number with 28.72 P/E and 67.64 EV/EBITDA
• ROCE of 6.63% indicates weak competitive moat and limited pricing power relative to capital requirements
• Minimal FCF yield of 1.3% leaves no cushion for disappointment or economic slowdown
• Missing growth metrics (N/A revenue/profit growth) prevents proper growth-to-price assessment

AI Analysis

IDEX presents a paradox that troubles me. On the surface, we see a well-managed industrial business with diversified end markets across health sciences, fluid metering, and safety products. The latest quarter showed solid 14.27% net margins and $538.9M in free cash flow—genuine cash generation that matters. The company demonstrates reasonable financial health with a 4.37 Altman Z-Score and modest 0.48 debt-to-equity ratio. However, I cannot ignore the valuation mathematics. At $197.60 with a Graham Number of just $45.71, we're paying 4.3 times what Graham's formula suggests is intrinsically safe. The P/E of 28.72 combined with an EV/EBITDA of 67.64 screams expensive for a business growing at undisclosed rates. The ROCE of 6.63% is particularly concerning—barely exceeding the cost of capital, suggesting limited competitive moat despite the diversified portfolio. A 1.3% FCF yield and negative 332% margin of safety indicate the market has priced in significant future growth that may not materialize. The Piotroski F-Score of 7/9 is respectable but not exceptional. While IDEX operates quality businesses, I cannot find a margin of safety at current prices—the first principle of value investing.

Bull Case

IDEX's diversified exposure to high-margin specialty markets in life sciences and industrial automation positions it well for long-term secular growth. Strong free cash flow generation and pricing power within niche markets could justify premium valuations if growth accelerates materially.

Bear Case

Current valuation leaves zero margin of safety for any disappointment. If growth falters or the company faces margin compression from competition, significant downside risk exists from current levels, particularly given ROCE barely covering cost of capital.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer